| Not Yet Recruiting | An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in P NCT07482891 | Shanghai 6th People's Hospital | Phase 4 |
| Not Yet Recruiting | Effect of Foot Reflexology On Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients NCT07322393 | University of Health Sciences Lahore | N/A |
| Not Yet Recruiting | This Study Will Investigate the Effectiveness of Peppermint Oil Inhalation in Reducing the Intensity and Frequ NCT06950632 | University of Health Sciences Lahore | N/A |
| Recruiting | Vomiting Prevention in Children With Cancer NCT06886451 | The Hospital for Sick Children | N/A |
| Recruiting | Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy NCT06850454 | Mahidol University | Phase 3 |
| Completed | To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting Afte NCT07081256 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia NCT06756022 | Anhui Provincial Children's Hospital | — |
| Completed | NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens NCT06331520 | Fudan University | Phase 3 |
| Recruiting | Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting NCT06120764 | Baskent University | N/A |
| Recruiting | Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer NCT06017284 | Fudan University | Phase 3 |
| Completed | Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients NCT05851625 | Indonesia University | N/A |
| Completed | Effectiveness of Laserpuncture and Standard Antiemetic on RINVR Scores in Adolescent Patients Undergoing Chemo NCT06121414 | Indonesia University | N/A |
| Unknown | Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy NCT06065722 | Simon Williamson Clinic | Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for t NCT05841849 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
| Recruiting | Serious Gaming for Chemotherapy-induced Nausea and Vomiting NCT05838638 | University of Central Florida | N/A |
| Completed | Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV NCT05805800 | Xingchen Peng | Phase 3 |
| Completed | A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting NCT05792228 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Terminated | Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vo NCT05590923 | The Guthrie Clinic | Phase 4 |
| Completed | The Effect of Mandala Technique on Acute Nausea-vomiting and Comfort Level in Cancer Patients NCT05885126 | Ege University | N/A |
| Completed | Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV) NCT05319860 | University of Miami | Phase 2 |
| Unknown | Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolesce NCT05346731 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 |
| Completed | Use of Aromatherapy to Reduce Symptom Burden NCT05251337 | Indiana University | Phase 2 |
| Unknown | Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC NCT05199818 | Xiamen LP Pharmaceutical Co., Ltd | Phase 3 |
| Completed | Anti-emetic Prophylaxis With or Without Dexamethasone NCT05242874 | Henan Cancer Hospital | Phase 3 |
| Completed | The Effect of Breathing Exercise on Chemotherapy-induced Nausea and Vomiting in With Autologous Hematopoietic NCT05311371 | Istanbul University - Cerrahpasa | N/A |
| Unknown | Granisetron Transdermal Patch System for Prevention of CINV by CapeOX NCT05325190 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer NCT05564286 | Shantou University Medical College | Phase 3 |
| Unknown | Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiti NCT04873284 | Shanghai Children's Medical Center | N/A |
| Terminated | Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting NCT05143554 | Medical College of Wisconsin | N/A |
| Completed | Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) NCT04817189 | Helsinn Healthcare SA | Phase 4 |
| Completed | Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants NCT04535141 | UNC Lineberger Comprehensive Cancer Center | Phase 3 |
| Withdrawn | Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting NCT04085393 | University of Alabama at Birmingham | Phase 2 |
| Unknown | Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy NCT04785495 | Instituto Brasileiro de Controle do Cancer | — |
| Completed | Prevalence of Delayed Chemotherapy Associated Nausea NCT04342780 | Antje Koller | — |
| Completed | Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV NCT04437017 | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 3 |
| Completed | Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Adv NCT03984214 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 3 |
| Completed | Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN) NCT04918069 | Christian Medical College, Vellore, India | Phase 2 |
| Completed | Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in NCT04054193 | Merck Sharp & Dohme LLC | Phase 4 |
| Withdrawn | Prevention of Unmitigated Chemotherapy-induced Emesis NCT03996863 | Otolith Labs | N/A |
| Completed | Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy NCT03948477 | University of Auckland, New Zealand | Phase 2 |
| Completed | Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea NCT03354741 | Centre Hospitalier Universitaire de Nice | N/A |
| Unknown | Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer NCT03571126 | Zunyi Medical College | Phase 4 |
| Completed | Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy NCT04075955 | CR-CSSS Champlain-Charles-Le Moyne | Phase 3 |
| Unknown | Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline NCT03740672 | Lei Li | — |
| Terminated | Low Dose Aprepitant for Patients Receiving Carboplatin NCT03237611 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Observational Study on the Use of Akynzeo® in Patients Receiving HEC NCT03649230 | Purdue Pharma, Canada | — |
| Unknown | the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets i NCT04430361 | Henan Cancer Hospital | Phase 2 |
| Unknown | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cispla NCT03668639 | Christina Ruhlmann | Phase 2 / Phase 3 |
| Unknown | The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy NCT03601871 | Yunpeng Liu | N/A |
| Unknown | Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vo NCT03478605 | Blokhin's Russian Cancer Research Center | Phase 2 |
| Completed | A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Co NCT03403712 | Helsinn Healthcare SA | Phase 3 |
| Unknown | Effect of tDCS of the Motor Cortex on Chemotherapy Induced Nausia and Vomiting NCT03405324 | Shereen Mamdouh | N/A |
| Completed | The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting NCT03232541 | Västernorrland County Council, Sweden | N/A |
| Completed | Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal NCT02909478 | Sun Yat-sen University | Phase 3 |
| Completed | Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers NCT03245918 | The Hospital for Sick Children | Phase 1 |
| Completed | Community-Led Action Research in Oncology: Improving Symptom Management NCT03208816 | Dartmouth-Hitchcock Medical Center | N/A |
| Completed | "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving H NCT03219710 | All India Institute of Medical Sciences | Phase 3 |
| Unknown | The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints NCT03061396 | Tianjin University of Traditional Chinese Medicine | N/A |
| Unknown | Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin NCT04201769 | Consorzio Oncotech | Phase 3 |
| Unknown | Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting NCT02933099 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 |
| Completed | Promoting Cancer Symptom Management in Older Adults NCT03143829 | University of Central Florida | N/A |
| Unknown | Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN NCT02970643 | Hee Jun Kim | N/A |
| Completed | NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer NCT03862144 | Consorzio Oncotech | Phase 2 |
| Completed | Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum NCT05512676 | Oslo University Hospital | — |
| Unknown | Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemo NCT02445872 | Zhejiang University | Phase 2 |
| Completed | A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vom NCT02517021 | Helsinn Healthcare SA | Phase 3 |
| Completed | An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Pr NCT02557035 | Helsinn Healthcare SA | Phase 3 |
| Terminated | Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevent NCT02519842 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Em NCT03674294 | Sun Yat-sen University | Phase 3 |
| Unknown | Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in NCT02478047 | Tianjin University of Traditional Chinese Medicine | N/A |
| Completed | Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vo NCT02484911 | First Affiliated Hospital of Harbin Medical University | Phase 3 |
| Completed | An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the NCT02434861 | Tesaro, Inc. | Phase 1 |
| Completed | Acupuncture for Chemotherapy-Induced Nausea and Vomiting NCT02195921 | Tianjin University of Traditional Chinese Medicine | N/A |
| Completed | Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting NCT02390648 | Mahidol University | Phase 2 |
| Unknown | The Effect of Acupuncture in Chemotherapy-induced Nausea and Vomiting NCT02369107 | Beijing Hospital of Traditional Chinese Medicine | N/A |
| Completed | A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolap NCT02382666 | Tesaro, Inc. | Phase 1 |
| Completed | An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant NCT02285647 | Tesaro, Inc. | Phase 1 |
| Unknown | Designed Music Narratives for the Reduction of Side Effects of Chemotherapy in Children (7-12 Years) With Canc NCT02583139 | University of Aarhus | N/A |
| Completed | Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail NCT02127255 | Beijing University of Chinese Medicine | N/A |
| Completed | A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC NCT02106494 | Heron Therapeutics | Phase 3 |
| Completed | Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility NCT02129478 | The Hospital for Sick Children | Phase 2 |
| Completed | Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy NCT02097823 | Indiana University | Phase 2 |
| Unknown | Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting NCT01993381 | The Catholic University of Korea | — |
| Terminated | Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma NCT01874119 | St. Louis University | Phase 2 |
| Completed | A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nause NCT01937156 | Solasia Pharma K.K. | Phase 3 |
| Completed | Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors NCT01736917 | Lawrence Einhorn | Phase 2 |
| Completed | Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention o NCT01697579 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomitin NCT01757210 | West Virginia University Healthcare | — |
| Completed | Fosaprepitant in Patients Receiving Ifosfamide-based Regimen NCT01490060 | M.D. Anderson Cancer Center | N/A |
| Completed | Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years NCT01596400 | Kyowa Kirin Pharmaceutical Development Ltd | Phase 1 |
| Completed | Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Ch NCT01500226 | Tesaro, Inc. | Phase 3 |
| Completed | Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Che NCT01499849 | Tesaro, Inc. | Phase 3 |
| Completed | Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients NCT01370408 | Northside Hospital, Inc. | Phase 2 |
| Completed | Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Che NCT01500213 | Tesaro, Inc. | Phase 3 |
| Unknown | Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting NCT01581918 | Faculdade de Medicina do ABC | Phase 2 |
| Unknown | Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients NCT02205164 | Associazione Salentina Angela Serra | Phase 2 |
| Completed | A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomitin NCT01362530 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in P NCT01442376 | Helsinn Healthcare SA | Phase 3 |
| Completed | Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemoth NCT01402024 | All India Institute of Medical Sciences | Phase 3 |
| Completed | An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting NCT01363479 | Helsinn Healthcare SA | Phase 3 |
| Completed | A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting NCT01376297 | Helsinn Healthcare SA | Phase 3 |
| Completed | Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting NCT01481831 | Shanghai Changzheng Hospital | Phase 4 |
| Completed | Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy NCT01346267 | University of South Florida | N/A |
| Completed | An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting NCT01339260 | Helsinn Healthcare SA | Phase 3 |
| Completed | Phase II Proof-of-concept Study of APD421 NCT01303978 | Acacia Pharma Ltd | Phase 2 |
| Completed | Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting NCT01012336 | Samsung Medical Center | Phase 2 |
| Completed | Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting NCT01387841 | Bharath Charitable Cancer Hospital and Institute | Phase 2 |
| Completed | Acupuncture for Chemical Therapy Induced Nausea and Vomiting NCT02842307 | Beijing University of Chinese Medicine | N/A |
| Withdrawn | A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic NCT00891761 | GlaxoSmithKline | Phase 3 |
| Terminated | A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy ( NCT00818259 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioa NCT00945321 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vom NCT00787566 | Shin Nippon Biomedical Laboratories, Ltd. | Phase 2 |
| Completed | Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiv NCT00553059 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Re-examination Study of EMEND (Aprepitant) (MK-0869-184) NCT01074255 | Merck Sharp & Dohme LLC | — |
| Completed | Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED) NCT00337727 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemot NCT00359567 | Taiho Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients Wit NCT01018758 | Gruppo Italiano Studio Linfomi | Phase 2 |
| Completed | To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting NCT00273468 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting NCT01031498 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) NCT00990821 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy NCT00104403 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041) NCT00211601 | Merck Sharp & Dohme LLC | N/A |
| Completed | Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Pati NCT00086762 | M.D. Anderson Cancer Center | N/A |
| Completed | Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106) NCT00972595 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED) NCT00971633 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nau NCT00642512 | Solvay Pharmaceuticals | Phase 3 |
| Withdrawn | Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years NCT01596413 | Kyowa Kirin Pharmaceutical Development Ltd | Phase 1 |
| Completed | An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in NCT00666783 | Xijing Hospital | Phase 2 |
| Withdrawn | Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years NCT01596426 | Kyowa Kirin Pharmaceutical Development Ltd | Phase 1 |